- Report
- April 2025
- 175 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- April 2025
- 175 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- April 2025
- 175 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- April 2025
- 250 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- March 2025
- 200 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- February 2025
- 200 Pages
Global
From €3991EUR$4,490USD£3,482GBP
- Report
- November 2025
- 181 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- August 2025
- 197 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- August 2025
- 189 Pages
Global
From €3151EUR$3,545USD£2,750GBP
€3501EUR$3,939USD£3,055GBP
- Report
- April 2025
- 200 Pages
Global
From €5653EUR$6,360USD£4,933GBP
€7066EUR$7,950USD£6,166GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1067EUR$1,200USD£931GBP
€1333EUR$1,500USD£1,163GBP
- Report
- April 2025
- 200 Pages
Global
From €5653EUR$6,360USD£4,933GBP
€7066EUR$7,950USD£6,166GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €1778EUR$2,000USD£1,551GBP
€2222EUR$2,500USD£1,939GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1422EUR$1,600USD£1,241GBP
€1778EUR$2,000USD£1,551GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1067EUR$1,200USD£931GBP
€1333EUR$1,500USD£1,163GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1067EUR$1,200USD£931GBP
€1333EUR$1,500USD£1,163GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1067EUR$1,200USD£931GBP
€1333EUR$1,500USD£1,163GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €889EUR$1,000USD£776GBP
€1111EUR$1,250USD£969GBP
- Report
- October 2025
Global
From €4355EUR$4,900USD£3,800GBP
- Report
- May 2025
- 100 Pages
Global
From €4355EUR$4,900USD£3,800GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more